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burden of cost on society (p  0.001). The largest portion of direct cost was devoted 
to medicines (46%) followed by laboratory investigations (32%). Comparing cost 
with family income, we also found that poorest segment of society is spending about 
18% of total family income on diabetes care. CONCLUSIONS: The overwhelming
cost threatens to stunt economic growth and undermines the living standard. The 
overall cost can be abridged by prevention of diabetes, earlier detection of disease and 
improved diabetes care. Prevention programs need to be initiated at lager scale to
enhance health gain to the individual and to reverse the advance of this epidemic. 
Policy makers need to ascertain the priority of diabetes education and prevention 
programs at primary health care outlets as an integral component.
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EXCESS COSTS OF DIABETES MELLITUS AMONG MEDICARE
RECIPIENTS IN A SKILLED NURSING FACILITY SETTING
Boulanger L1, Kongsø JH2, Bouchard JR3, Christensen T4, Fraser K1, Russell MW1
1Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, 2Novo Nordisk A/S, Bagsvaerd, 
Denmark, 3Novo Nordisk, Inc., Princeton, NJ, USA, 4Novo Nordisk A/S, Bagsværd, Denmark
OBJECTIVES: This retrospective matched cohort study compared resource utilization
and costs between diabetic and non-diabetic patients requiring skilled nursing facility
(SNF) admissions. METHODS: Patients with a SNF admission for at least 30 days 
during 2004 were identiﬁ ed from a 5% random sample of Medicare patients. The 
“diabetes” cohort consisted of patient with an ICD-9-CM diagnosis on 1 SNF claims. 
Each diabetes patient was matched (by age, sex, and race) with one patient having no
diabetes claims in 2004 and followed for 12 months. The diabetes and non-diabetes
cohorts were compared, both overall and within subgroups deﬁ ned by age, with 
respect to rates of diabetes complications/conditions and co-morbid conditions, health
care resource utilization, and Medicare payments in 2005. Ordinary least squares 
regression was used to estimate adjusted costs controlling for comorbid conditions
(i.e., selected chronic conditions, Charlson comorbidity score). RESULTS: We identi-
ﬁ ed 20,477 diabetic patients and 78,154 non-diabetic patients in 2004. Following
matching, there were 20,158 in each group (45% aged 80 years, 62% female, 82%
white). Relative to matched controls, diabetic patients had higher Charlson comorbid-
ity scores and were more likely to have complications such as congestive heart failure 
(24.1% vs. 18.1%, p  0.01) and renal disease (11.2% vs. 6.7%, p  0.01). On
average, diabetic patients had an additional one-half day (p  0.01) in the hospital 
over one year of follow-up. Total unadjusted mean Medicare payments were greater 
among diabetic patients than controls ($26,075 vs. $24,622, p  0.01), primarily due
to differences in inpatient costs. After adjusting for comorbidities, total costs were 
$969 higher among diabetic patients (p  0.01). Excess costs were greater among 
patients 70 years ($1269, p  0.01) versus those 70 years ($892, p  0.01). CON-
CLUSIONS: These ﬁ ndings suggest that diabetic patients in skilled nursing facilities
had higher health care costs than non-diabetic patients even after controlling for
complications related to diabetes and chronic comorbidity.
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OBJECTIVES: Morbidity, mortality, and costs of Type 2 Diabetes (T2D) remain high 
despite the available efﬁ cacious treatment options. New agents have shown improve-
ments in A1C and other surrogates but long-term impacts are unknown. METHODS:
Data from randomized controlled trial of liraglutide monotherapy (LEAD 3) was used 
to determine long-term consequences of treatment with liraglutide, a new OD GLP-1 
analog, compared to glimepiride in a simulated 30-year follow-up. The CORE diabetes 
model, calibrated to LEAD 3 baseline patient characteristics, employed data from 
long-term studies to project morbidity, mortality and costs of T2D. We simulated
clinical and economic consequences of patients receiving liraglutide 1.2mg and 1.8mg
compared to glimepiride 8 mg, all as monotherapy, for treatment of T2D. The effect
of treatment on A1C, SBP, lipids, weight and risk of hypoglycemia was taken into
account. Survival, cumulative incidence of CV, ocular, renal events and costs (dis-
counted 3%/yr) were estimated over three periods: 10, 20, 30 years. RESULTS: Simu-
lations produced higher survival rates for liraglutide 1.8 mg and 1.2 mg compared to
glimepiride after 30 years’ follow-up (16.5%, 13.6%, 7.3%, respectively). Highest
difference in fatal events across treatment groups related to end-stage renal disease, 
although the main cause of death in all groups was associated with CV events. Non-
fatal renal and ocular events were lower for both liraglutide doses. Neuropathies that
led to a ﬁ rst or recurrent amputation were higher for glimepiride compared to the 
liraglutide doses. The average cumulative cost per patient was US$9367 higher for
glimepiride at year 30, compared to liraglutide 1.8mg, and US$6491 higher than 
liraglutide 1.2 mg. CONCLUSIONS: The main cost component for all groups was
management of CV events. Using the CORE model and data from LEAD 3, projected
survival, diabetes complications and costs over the long term favored liraglutide 
1.2 mg and 1.8 mg compared to glimepiride in the treatment of T2D.
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OBJECTIVES: Poor control of type 2 diabetes (T2D) results in substantial morbidity
and economic burden to the health care system. Studies of new T2D treatments are
rarely designed to assess mortality, complication rates and costs. We sought to estimate 
long-term consequences of liraglutide and rosiglitazone both as add-on to glimepiride. 
METHODS: To estimate clinical and economic consequences, we used the CORE 
diabetes model, a validated cohort model that uses data from long-term clinical trials
to simulate morbidity, mortality and costs of T2D. Clinical data were extracted from 
the randomized double-blinded placebo-controlled LEAD 1 trial evaluating two doses 
(1.2 mg and 1.8 mg) of a once daily human GLP-1 analog liraglutide, or rosiglitazone
4 mg, added to glimepiride. The CORE diabetes model was calibrated to the LEAD 1
baseline patient characteristics. Survival, cumulative incidence of cardiovascular, ocular 
and renal events and costs were estimated over three periods: 10, 20 and 30 years.
RESULTS: In a cohort of 5000 patients per treatment followed for 30 years, liraglutide 
1. mg and 1.8 mg had higher survival compared to the group treated with rosiglitazone 
(15.0% and 16.0% vs. 12.6% after 30 years), and fewer cardiovascular, renal, and
ocular events. Cardiovascular deaths after 30 years were 69.7%, 68.4% and 72.5%,
for liraglutide 1.2 mg, 1.8 mg, and rosiglitazone, respectively. First and recurrent 
amputations were lower in the rosiglitazone group compared to both doses of liraglu-
tide (number of events: 565, 529 and 507 for liraglutide 1.2 mg, 1.8 mg, and rosigli-
tazone, respectively). CONCLUSIONS: Overall cumulative costs per patient were 
lower in both liraglutide groups compared to rosiglitazone mainly driven by the costs
of cardiovascular events (US$38,963, $39,239, and $40,401 for liraglutide 1.2 mg, 
1.8 mg, and rosiglitazone, respectively). Projected survival and long term outcomes 
favored liraglutide 1.2 mg and 1.8 mg over rosiglitazone both added to glimepiride.
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OBJECTIVES: Among patients diagnosed with diabetic peripheral neuropathic pain 
(DPNP); whether adherence to duloxetine therapy was correlated with opioid medica-
tion use and health care expenditures. METHODS: Diabetic patients who were dis-
pensed duloxetine between March 1, 2005 and December 31, 2005 were identiﬁ ed 
from a large administrative claims database and an “index date” was assigned based
on the dispense date of the ﬁ rst duloxetine claim. Included patients were 18 to 64 
years old, diagnosed with DPNP in the one year prior to the index date, and received 
opioids in the prior 90 days. Adherence to duloxetine therapy was based on medica-
tion possession ratio (MPR), and patients were dichotomized as “continuous” (MPR
q 0.8) and “non-continuous” (MPR  0.8) users. We examined changes in short-acting 
(SA) and long-acting (LA) opioid utilization one year before and after the index date. 
One year health care utilization and costs were also examined. Multivariate linear 
regressions were performed to examine the association between duloxetine adherence 
and study outcomes, controlling for baseline demographic and clinical characteristics.
RESULTS: We identiﬁ ed 97 continuous users and 245 non-continuous users of dulox-
etine. Compared with non-continuous patients, continuous users had a greater reduc-
tion in days on SA hydrocodone (30.2, p  0.05), number of SA hydrocodone 
prescriptions (1.7, p  0.05), and days on DPNP-related SA opioids (23.8, p  0.05). 
We did not observe any signiﬁ cant reduction in LA opioid use. Continuous users also
had 40% fewer inpatient stays (p  0.05) and fewer days in hospital (3.5, p  0.05). 
In the regression model, we found continuous users had $17,062 less (p  0.05) total 
health care cost than non-continuous users mainly attributable to lower inpatient costs 
($16,932, p  0.05). The outpatient and pharmacy costs were similar between cohorts.
CONCLUSIONS: Continuous duloxetine users were more likely to have a reduction
in SA opioids use and have lower hospital expenditures than non-continuous dulox-
etine users.
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OBJECTIVES: study compared the daily average consumption (DACON) of insulin 
detemir (DET), insulin glargine (GLAR) and NPH insulin in patients with T2D in a
real-world setting. METHODS: Patients with T2D (per ICD-9 code 250.x1 250.x3)
newly treated with DET, GLAR or NPH insulin monotherapy were identiﬁ ed in the 
Verispan Electronic Data Warehouse (SDI, Plymouth Meeting, PA) from 7/1/2006 to 
6/31/2007. A study limitation is that Verispan data has an open architecture and does
not include eligibility data, but ﬁ ltering techniques were employed to eliminate cohort 
shrinkage. A patient level DACON was calculated as the number of insulin units dis-
pensed from the ﬁ rst to the second to last prescription in the observation period 
divided by the elapsed days from the ﬁ rst to last ﬁ ll. Unpaired t-tests and chi-square 
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tests were used to identify differences between GLAR or NPH and DET for continuous 
and categorical variables respectively. A Wilcoxon rank sum test was used to identify
differences in mean DACON between GLAR or NPH and DET. RESULTS: Of the
21,881 patients identiﬁ ed, 2215 (10.1%) were treated with DET, 16,548 (75.6%) with 
GLAR, and 3118 (14.3%) with NPH. A higher percentage of NPH users were above
65 years (42.4%) compared to GLAR (35.2%) and DET (31.2%) (p  .001). Mean/
median DACON as units/day were 35/26 for DET, 32/27 for GLAR (p  0.06) and 
41/32 for NPH (p  .001). A higher percentage of DET patients had prior antidiabetic
use compared to GLAR and NPH users (75.8%, 67.8% 52.3% respectively, p  .001). 
The percentage using multiple antidiabetic agents before the observation period was 
highest for DET (56.3%), followed by GLAR (45.7%) and NPH (29.5%) (p  .001).
CONCLUSIONS: DACON was highest with NPH and did not vary between DET
and GLAR. A greater proportion of DET patients were treated with multiple antidia-
betic agents prior to insulin start, suggesting more severe diabetes.
DIABETES/ENDOCRINE DISORDERS – Patient-Reported 
Outcomes Studies
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OBJECTIVES: To examine the effect of medication choice between duloxetine and 
pregabalin on medication compliance outcomes among patients with diabetic periph-
eral neuropathic pain (DPNP). METHODS: A retrospective cohort study design was
used with a large US national commercial health care claims database over 2005–
2007. Patients aged 18–64 who dispensed duloxetine or pregabalin in 2006 were
selected, with the ﬁ rst dispense date as the “index date.” All individuals included were
diagnosed with DPNP in the 12-month pre-index period, and continuously enrolled 
in both the 12 months pre- and post-index periods. Duloxetine and pregabalin cohorts 
were constructed based on the initial agent. Propensity score analysis was used to 
control for cross-cohort differences in demographics, pre-index clinical and economic
characteristics, and pre-index treatment patterns. Medication compliance outcomes
were examined between cohorts via medication possession ratio (MPR) and pro-
portion of patients with MPR q 80%. RESULTS: Both the duloxetine (n  603) and 
pregabalin (n  1,751) cohorts had the mean age around 55 years (54.9 vs. 55.6).
Many duloxetine and pregabalin patients had cardiovascular disease (86.9% vs.
89.0%), neuropathic pain other than DPNP (80.3% vs. 83.2%), hypertension (78.8% 
vs. 82.6%), osteoarthritis (52.2% vs. 53.1%), and used anticonvulsants (36.3% vs. 
35.6%) and opioids (32.2% vs. 28.4%). Controlling for demographics, pre-index 
clinical and economic characteristics, and prior medication history, duloxetine patients 
had signiﬁ cantly higher MPR than pregabalin patients (75.8% vs. 52.9%, p  0.05). 
The proportion of patients with MPR q 80% was also signiﬁ cantly higher among 
patients in the duloxetine cohort (47.4% vs. 27.6%, p  0.05). CONCLUSIONS: In
a real world setting, medication compliance measured by MPR or proportion of 
patients with MPR q 80% was statistically signiﬁ cantly higher among DPNP patients 
treated with duloxetine than those on pregabalin. The results suggest that medication
choices between duloxetine and pregabalin had statistically signiﬁ cant effects on 
medication compliance outcomes.
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OBJECTIVES: To evaluate patterns of medication use in Type II diabetes patients and
to assess risk factors associated with non-adherence/non-persistence to drug therapy. 
METHODS: Administrative claims data (2003–2006) were used to identify newly
diagnosed patients aged q30 years with at least one oral antidiabetic(OAD) prescrip-
tion. Patterns of medication use(augmentation, switch, gap) were evaluated. Medica-
tion possession ratio(MPR) 0.8 and proportion of days covered(PDC) 0.8 were
deﬁ ned as non-adherence to the index and any OAD medication, respectively. Persis-
tence was assessed for medication discontinuation(gap q 90 days) and time to discon-
tinuation. Logistic regression and Cox models were performed to investigate signiﬁ cant 
factors of non-adherence/non-persistence. RESULTS: A total of 7799 patients were 
identiﬁ ed. Patients initiated on biguanides(16%) were less likely to augment with
another drug as compared to those on other medications(19%, p  0.0001). Patients 
on ﬁ xed dose medication(FDM) thiazolidinedione & biguanide were more likely to
switch(26%) and discontinue(64%), but less likely to experience a gap(37%) as com-
pared to other medication cohorts(a5% for switch, a45% for discontinuation, and 
q38% for gap). They were also least adherent to their index drug(16%), but their 
adherence rate to any OAD medication increased to 42%. Signiﬁ cant variables 
associated with non-adherence/discontinuation of drug therapy included younger age 
(65 years) (OR  5.19 vs. q65 years, HR  0.98, for non-adherence and discontinu-
ation, respectively), fewer number of drugs taken (OR  0.95, HR  0.98), female 
(OR  1.34, HR  1.19), initiation on monotherapy or FDM(OR  1.62, HR  1.39), 
and increasing comorbidity(OR  1.20, HR  1.22). Signiﬁ cant factors also associated 
with discontinuation included not augmenting(HR  0.83), switching medications(HR 
 2.64), and no medication gap(HR  0.23). CONCLUSIONS: Index medication 
played an important role in medication compliance based on non-adherence and
non-persistence measures. Intervention/disease management programs designed to 
improve medication compliance should be tailored according to index medication, 
especially for those initiated on FDM thiazolidinedione & biguanide, for which
patients displayed less optimal medication use patterns and were more likely to dis-
continue drug therapy.
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OBJECTIVES: The objective of the current study is to explore the impact of treatment
complexity on patient behavior and subsequent glycemic control among type 2
diabetics (T2DM). METHODS: This was a retrospective evaluation of T2DM patients
continuously enrolled in a national health plan during 2000–2007. Patients with a 
T2DM diagnosis, naïve to OADs, and not using insulin were included. A treatment 
complexity score was assigned based on dosage form, usage frequency, and special 
directions (e.g. with food, time of day) with higher values indicating higher complexity.
Adherence was calculated as a medication possession ratio (MPR) weighted by time
on each OAD during a 1-year period. Baseline and follow-up A1c values were obtained 
for those with laboratory data. Logistic and linear multivariate regressions were con-
ducted, controlling for patient demographics, baseline A1c and comorbidities. 
RESULTS: A total of 94,860 patients were identiﬁ ed, 16,198 with A1c values.
Mean age was 52.6 years, 55% male, 78% initiated on monotherapy (48% metfor-
min, 17% sulfonylurea), and 20% initiated on 2 OADs. Mean treatment complexity 
score was 3.33 (range 0–14), 29% were considered low complexity (0–2 points), 57% 
medium complexity (2–5), and 14% high complexity (5). Mean 1-year adherence 
to OAD therapy was 75%, 73% and 69% for low, medium and high complexity. 
After controlling for confounders, the odds of being adherent (MPR q 80%) were 
19% and 43% lower for medium and high complexity, versus low complexity regi-
mens (p  0.0001). Mean baseline and follow-up A1c values were 8.20% and 6.56%. 
After controlling for confounders, follow-up A1c values were predicted to be 0.36% 
lower among adherent patients than non-adherent patients. CONCLUSIONS: The 
complexity of diabetes treatments has negative effects on adherence, which results in 
poor glycemic control. Less complex diabetes treatments (i.e. less dosing frequency 
and no special directions) may offer improvements in patient adherence and subse-
quent A1c values.
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OBJECTIVES: Hybrid applications of conventional exact covariate matching and 
propensity score concepts have recently been explored in the literature. In this research, 
we examine the advantages and disadvantages of hybrid usage of these two principles.
Speciﬁ cally, we evaluate the impact on comparable samples and treatment persistence
measures from retrospective prescription claims data. METHODS: Patient persistence 
on anti-diabetic agents (Exenatide and Insulin Glargine) was used to compare six 
hybrid matching algorithms proposed by Yang and Stemkowski (2008), using 
IMS’ LifeLink longitudinal prescription database (LRx). Persistence was evaluated
by persistent days on quartiles, persistence rate over time, survival censoring
rate, Kaplan-Meier survival curves and Cox Proportional Hazard Model. The 
hybrid matching algorithms were compared on run time, matching rate and bias 
reduction. RESULTS: Directly matched cohorts resulted in more comparable
samples and improved the evaluation on treatment persistence relative to pre-matched 
sample. When propensity score played as a caliper, the matching process resulted
in un-balanced variables and exhibited the weakest ability in bias correction due 
to the least drop in standardized difference. This was the only method among the 
six that failed assumption tests in the survival analysis (P  0.05). Conversely, among 
all other algorithms where all factors were balanced, the algorithm in which pro-
pensity score acted in a parenting role had the least running time and greatest 
bias reduction, which was displayed by the largest decline in standardized difference.
The smallest values in Fit-of-Statistics through the whole study period also indicated 
the strongest hold of assumptions in the Cox proportional hazard model, relative 
to the other ﬁ ve algorithms. CONCLUSIONS: In the assessment of treatment 
persistence through survival analysis, the role of propensity score as a parenting
factor in the selection of matched samples outperformed alternative hybrid match-
ing algorithms. In contrary, use of propensity score as a caliper factor, was least
satisfactory.
